A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors

NCT02795767 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia A

Interventions

DRUG: Emicizumab

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]